Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging

Lavinia Morosi1, Cristina Matteo1, Tommaso Ceruti1

  • 1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Oncology.

Insights

Mass spectrometry imaging visualizes anticancer drug distribution in tumors. Niraparib showed more homogeneous distribution than olaparib, offering insights into drug efficacy and resistance mechanisms.

Area of Science:

  • Oncology
  • Pharmacology
  • Analytical Chemistry

Background:

  • Optimal anticancer drug distribution within tumors is crucial for therapeutic efficacy.
  • Traditional methods like LC-MS/MS lack spatial information on drug concentration.
  • Mass spectrometry imaging (MSI) offers high spatial resolution and specificity for visualizing drug distribution.

Purpose of the Study:

  • To develop and validate a quantitative MSI method for visualizing PARP inhibitors (PARPi) niraparib and olaparib distribution in ovarian tumors.
  • To compare the intratumor distribution of niraparib and olaparib using MSI.
  • To investigate the impact of P-glycoprotein (P-gp) expression on niraparib distribution.

Main Methods:

  • Inorganic nanoparticles were used as matrices for MSI analysis of niraparib and olaparib.
  • Deuterated internal standards and a custom preprocessing pipeline were employed for single-pixel quantification.
  • Quantitative MSI data were validated for precision, accuracy, linearity, repeatability, and limit of detection.

Main Results:

  • A validated quantitative MSI method was established for niraparib and olaparib in mouse ovarian tumors.
  • MSI revealed differential tumor penetration, with niraparib showing more homogeneous distribution and higher exposure than olaparib.
  • Niraparib distribution was heterogeneous in tumors overexpressing P-gp, suggesting a potential resistance mechanism.

Conclusions:

  • This study demonstrates the first quantitative spatial distribution of PARPi in tumor tissues using MSI.
  • The distinct tumor distribution patterns of niraparib and olaparib have potential clinical implications for treatment strategies.
  • MSI is a valuable tool for pharmacokinetic studies, drug discovery, and understanding drug resistance mechanisms.

Related Concept Videos